Bob Scribner, CEO



Experienced startup life science executive with a broad background in life science development and commercialization. Bob has built teams and lead technology development programs in cardiology, orthopedics, and life science applications, and successfully conducted international IDE clinical studies leading to FDA approval, CE Mark and market creation for new technology. 

Mark Borden PhD, CSO



As an Assoc. Professor, Mechanical Engineering and Fellow, Materials Science & Engineering at The University of Colorado,  Mark specializes in research on the engineering of colloidal theranostic (therapy + diagnostic) devices for medical imaging and therapy. Founder and inventor of oxygen microbubbles, Mark’s current research is directed to oxygen microbubbles for oxygen delivery to hypoxic tissue, and novel agents for targeted DNA delivery to solid tumors.

Paul Mountford PhD, Dir. R&D



University of Colorado PhD, performing research on Phase-Change Microbubbles with The Borden Group. Industry experience includes broad development of materials and methods for microbubbles in ultrasound imaging and therapy (treatment of stroke, other neurodegenerative diseases), targeted cavitation, DNA fragmentation, and superheated nanoemulsions.

Robby Scribner, Dir. Operations


 Project Manager responsible for developing and sustaining QMS functions for medical device products in startup to Fortune 500 organizations. Responsible for Quality System implementation, design controls, risk analysis, verification/validation testing, process validation, and design of lean manufacturing cells (Toyota Production System) within ISO 13485 and FDA regulated environments.